Dashboard
Manage Tickers

RHHBYROCHE HOLDING LTD

N/A


$ 0.43 (1.05 %)    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 483.48 $ 2.36 (0.49 %)
DIA $ 409.35 $ 0.12 (0.03 %)
SPY $ 561.48 $ 1.55 (0.28 %)
TLT $ 99.15 $ 0.47 (0.48 %)
GLD $ 232.75 $ 1.09 (0.47 %)
$ 41.45
-- x --
-- x --
-- - --
$ 29.20 - $ 41.47
618,359
na
0
$ 0.45
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

roche-misses-out-on-weight-loss-blockbuster-drug-now-playing-catch-up-in-booming-market
Roche Misses Out On Weight-Loss Blockbuste...
08/16/2024 17:56:16

Roche missed out on acquiring a potential blockbuster weight-loss drug, now owned by Eli Lilly, in 2018. The drug, orforglipron...

why-is-small-cap-tempest-therapeutics-stock-trading-higher-on-thursday
Why Is Small-Cap Tempest Therapeutics Stoc...
08/15/2024 17:15:33

Tempest Therapeutics receives FDA feedback on the Phase 3 trial design for amezalpat (TPST-1120) in combination with Tecentriq ...

cancer-focused-syros-pharmaceuticals-stops-mid-stage-leukemia-combo-therapy-study-cites-disappointing-unexpected-outcome
Cancer-Focused Syros Pharmaceuticals Stops...
08/13/2024 13:41:17

Syros Pharmaceuticals announces discontinuing enrollment in the SELECT-AML-1 Phase 2 trial due to the low probability of demons...

merck-stops-lung-cancer-study-for-keytruda-combo-due-to-ineffective-results-side-effects
Merck Stops Lung Cancer Study For Keytruda...
08/08/2024 15:51:24

Merck discontinues the Phase 3 KeyVibe-008 trial for the fixed-dose combination of vibostolimab and Keytruda in extensive-stage...

roche-considers-selling-cancer-data-specialist-flatiron-health-business-highlights-challenges-with-start-up-acquisitions
Roche Considers Selling Cancer Data Specia...
08/07/2024 15:25:56

Roche considers divesting Flatiron Health, acquired for $1.9 billion in 2018, highlighting the challenges big pharma faces with...

bristol-myers-squibb-terminates-cancer-drug-development-program-with-agenus
Bristol Myers Squibb Terminates Cancer Dru...
08/05/2024 18:31:11

Agenus reports that Bristol Myers Squibb (NYSE: BMY) is ending their 2021 agreement, returning the TIGIT bispecific antibody AG...

Core News & Articles
Roche Holding H1 Adj. EPS CHF 10.23 Up Fro...
07/25/2024 07:38:08

novo-nordisks-stock-dips-in-pre-market-despite-winning-uks-approval-of-weight-loss-drug-whats-going-on
Novo Nordisk's Stock Dips In Pre-Market De...
07/24/2024 10:57:33

Wegovy, a GLP-1 receptor agonist, had previously been approved for use in obesity treatment and weight management.

oral-weight-loss-drugs-vs-injections---pills-are-promising-yet-challenging-frontier
Oral Weight Loss Drugs Vs. Injections - Pi...
07/22/2024 17:42:06

Pharmaceutical giants like Roche, Eli Lilly, Novo Nordisk, and Pfizer are racing to develop oral weight loss medications. These...

vix-stages-double-digit-spike-as-risk-off-takes-over-chipmakers-fail-to-rebound-weight-loss-giants-eli-lilly-novo-tumble-whats-driving-markets-thursday
VIX Stages Double-Digit Spike As Risk Off ...
07/18/2024 18:05:28

It’s another risk-off day on Wall Street, with all major U.S. indices trading in the red. The CBOE Volatility Index (VIX), ofte...

pfizer-and-roche-advance-on-their-weight-loss-drug-journeys
Pfizer And Roche Advance On Their Weight L...
07/17/2024 14:48:52

After previously discounting a twice-daily version of its weight loss drug due to patients having difficulties tolerating it, P...

obesity-drugs-focused-stocks-tumble-on-wednesday---whats-going-on-with-eli-lilly-novo-nordisk-viking-therapeutics-structure-therapeutics
Obesity-Drugs Focused Stocks Tumble On Wed...
07/17/2024 14:47:40

Eli Lilly, Novo Nordisk, Viking Therapeutics, and Structure Therapeutics shares are down following Roche's promising CT-996...

Core News & Articles
Benzinga Market Summary: Chip Stocks Fall ...
07/17/2024 13:33:51

roche-highlights-encouraging-data-from-newly-acquired-second-weight-loss-drug-candidate-in-early-stage-study
Roche Highlights Encouraging Data From New...
07/17/2024 11:28:26

Roche reported promising topline results from a Phase 1 trial of CT-996, an oral GLP-1 receptor agonist for type 2 diabetes and...

Core News & Articles
Roche's Genentech Reveals Phase I Results ...
07/17/2024 05:48:02

After four weeks of treatment, CT-996 demonstrated clinically meaningful weight loss of -7.3% (weight loss in placebo -1.2%; ...

roches-new-immunotherapy-fails-to-show-benefit-over-mercks-blockbuster-keytruda-in-lung-cancer-patients
Roche's New Immunotherapy Fails To Show Be...
07/05/2024 12:09:50

Roche's SKYSCRAPER-06 study of tiragolumab plus Tecentriq and chemotherapy did not meet primary endpoints for progression-f...

Core News & Articles
Reported Thursday, Roche's Genentech Halts...
07/05/2024 06:54:20

SKYSCRAPER-06 evaluating tiragolumab plus Tecentriq and chemotherapy did not meet the primary endpoints of progression-free s...

Core News & Articles
Roche's Genentech Receives FDA Approval Fo...
07/05/2024 05:57:17

Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that...

abbviegenmabs-epkinly-fda-approval-is-a-positive-step-analyst-says-additional-expansion-opportunities-underway
AbbVie/Genmab's Epkinly FDA Approval Is A ...
06/27/2024 17:22:09

The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractor...

supreme-court-backs-pharmaceutical-giants-in-iraq-terrorism-funding-case
Supreme Court Backs Pharmaceutical Giants ...
06/24/2024 19:47:37

The U.S. Supreme Court supports pharmaceutical companies, led by AstraZeneca, in a lawsuit accusing them of funding terrorism i...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION